Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Are midsagittal tissue bridges predictive of outcome after cervical spinal cord injury?

MPG-Autoren
/persons/resource/persons188373

Freund,  Patrick
Balgrist Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland;
Wellcome Trust Centre for Neuroimaging, University College London, United Kingdom;
Department of Brain Repair & Rehabilitation, University College London, United Kingdom;
Department Neurophysics (Weiskopf), MPI for Human Cognitive and Brain Sciences, Max Planck Society;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Huber, E., Lachapelle, P., Sutter, R., Curt, A., & Freund, P. (2017). Are midsagittal tissue bridges predictive of outcome after cervical spinal cord injury? Annals of Neurology, 81(5), 740-748. doi:10.1002/ana.24932.


Zitierlink: https://hdl.handle.net/11858/00-001M-0000-002D-25F1-0
Zusammenfassung
T2-weighted scans provided data on the extent and dynamics of neuronal tissue damage and midsagittal tissue bridges at the epicenter of traumatic cervical spinal cord lesions in 24 subacute tetraplegic patients. At one month post-injury, smaller lesion area and midsagittal tissue bridges identified those patients with lower extremity evoked potentials and better clinical recovery. Wider midsagittal tissue bridges and smaller lesions at one month post-injury were associated with neurological and functional recovery at 1 year follow-up. Neuroimaging biomarkers of lesion area and midsagittal tissue bridges are potential outcome predictors and patient stratifiers in both subacute and chronic clinical trials.